The basis for the selection of these patients was that tumor samples to perform whole-exome sequencing (WES) were available and that they all had positive IFNγ enzyme-linked immunospot (ELISpot) responses when post-vaccination peripheral blood mononuclear cells (PBMC) samples were stimulated with the vaccine lysate (18, 20, 26). Here, IFNG is linked to neoplasm.